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ABSTRACT 
Introduction: The objective of this study was 
to evaluate efficacy, local tolerability, and 
safety of this first-in-class preservative-free 
prostaglandin preparation in patients with 
ocular hypertension and glaucoma. Methods: 
Patients with glaucoma or ocular hypertension 
who required a change of medication or were 
naïve to treatment were included in this 
noninterventional and observational study. 
Noninterventional means that no influence 
was made upon the decision of the physicians 
to include specific patients and upon the 
treatment algorithm used. German law for 
observational studies does not allow any 
influence on the choice of drugs used, patient 
selection, masking, and comparator treatment 
regimens. The main aim of this observational 
study was to collect “real-life data” on the 
efficacy and safety of a new medical treatment 
after approval in a large patient population. 
Participating ophthalmologists were asked 
to provide anonymous patient data collected 
during regular visits by filling a simple data 
entry form. Intraocular pressure (IOP) readings 
were recorded at baseline (previous therapy 
or untreated) and 6-12 weeks after changing 
medical treatment to or initiating treatment 
with preservative-free tafluprost once daily. 
Changes in the IOP were evaluated over 
the study period for all patients as well as 
for specific pretreatment subgroups. Local 
comfort was determined using a five-point 
scale (very good, good, satisfactory, less 
satisfactory, not acceptable) before and after 
the change of medical treatment. All adverse 
events were recorded. Results: Data from 
2123 patients with glaucoma or ocular 
hypertension were considered for the final 
evaluation. Medication was changed in 
41.1% of patients due to tolerability issues 
and in 25.6% of patients due to insufficient 
efficacy with prior medication. In all patients 
preservative-free tafluprost 0.0015% lowered 
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IOP from 19.5±4.4 mmHg (baseline) to 
16.4±2.9 mmHg after 6-12 weeks. Preservative-
free tafluprost also significantly lowered 
the IOP in all monotherapy subgroups: 
treatment-naïve patients (n=440): 22.6±3.9 
mmHg (baseline) to 16.7±2.7 mmHg (week 
6-12); beta blockers (n=307): 20.3±3.5 mmHg 
(baseline) to 16.7±2.6 mmHg (week 6-12); 
carbonic anhydrase inhibitors (n=158): 
19.0±3.6 mmHg (baseline) to 16.0±2.6 mmHg 
(week 6-12); prostaglandin analogs (PGAs; 
n=447): 16.8±2.9 mmHg (baseline) to 15.8±2.6 
mmHg (week 6-12). Local comfort was rated 
as “very good” or “good” by 85.6% of patients 
at the final visit (P<0.001). Only few adverse 
events occurred during the treatment period: 
18 patients (0.8%) discontinued medical 
treatment with preservative-free tafluprost due 
to local intolerance; six patients (0.3%) due to 
efficacy issues; four patients complained about 
systemic side effects (0.2%); and two patients 
preferred to use a multidose treatment regimen 
(0.2%). Conclusion: Although this study was 
limited by its observational design the results 
demonstrate that preservative-free tafluprost 
0.0015% was effective, generally well tolerated, 
and safe in a broad and heterogeneous patient 
population. 
Keywords: glaucoma; ocular hypertension; 
ocular surface disease;  preservatives; 
prostaglandin analogs; tafluprost
INTRODUCTION
Glaucoma is the second leading cause 
of blindness worldwide: an estimated 
60.5 million people will have glaucoma by 2010, 
increasing to 79.6 million by 2020.1 The disease 
is characterized by a progressive loss of retinal 
ganglion cells leading to optic nerve atrophy and 
visual field defects. The etiology of glaucoma 
is probably multifactorial, however, increased 
intraocular pressure (IOP) is considered to be 
the most important risk factor and, thus far, is 
the only risk factor that can be modified.2 Major 
outcome studies have shown that lowering IOP 
is beneficial for patients with primary open-angle 
glaucoma, normal-tension glaucoma, and ocular 
hypertension.2-6 Worldwide, prostaglandins have 
become the major therapeutic class for medical 
treatment of glaucoma because of their excellent 
efficacy and favorable safety profile.7 Tafluprost 
is a novel prostaglandin that has been approved 
for ophthalmic use in a number of markets 
worldwide. Tafluprost is highly selective for 
the prostaglandin FP-receptor.8 The drug is the 
first and only prostaglandin that is available 
in a preservative-free formulation for the 
treatment of patients with glaucoma and ocular 
hypertension. In controlled clinical studies the 
drug lowered IOP effectively and was generally 
well tolerated.9-11 
Numerous experimental and clinical studies 
clearly demonstrate that the long-term use of 
preserved topical drugs may induce side effects 
at the ocular surface. The most frequently used 
preservative, benzalkonium chloride (BAC), 
has consistently been shown to induce toxic 
effects in laboratory, experimental, and clinical 
studies. BAC is proapoptotic, proinflammatory 
and causes tear film instability and loss 
of goblet cells.12-15 These changes cause 
irritation, ocular discomfort, and subjective 
visual complaints. Furthermore, more severe 
side effects, such as chronic inflammation or 
a progressive development of fibrosis, may 
increase the risk of failure after glaucoma 
filtering surgery.16,17 Therefore, preservative-
free medications may be beneficial for many 
glaucoma patients. 
The purpose of the present study was to 
evaluate the efficacy, local tolerability, and 
safety of preservative-free tafluprost 0.0015% 
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This study was a prospective, multicenter, 
noninterventional, observational, open-label 
study conducted in Germany between July 2009 
and February 2010. Patients with glaucoma 
or ocular hypertension who the investigators 
determined to require a change of medication, 
an add-on therapy, or who were treatment 
naïve were followed for 6-12 weeks after they 
were switched to once-daily therapy with 
preservative-free tafluprost 0.0015% (Taflotan®, 
Taflotan® sine, Tapros®, Santen Pharmaceutical 
Co., Ltd., Osaka, Japan, Saflutan® Merck & Co. 
Inc., USA) or after initiation of medical treatment 
(treatment-naïve patients). Six hundred and 
sixty-one participating ophthalmologists 
provided anonymous patient data using a 
standardized data-collection instrument. 
The study treatment was based only on the 
decision of the physician and their reasons for 
prescribing the new medication were collected. 
German law does not require informed consent 
for this type of noninterventional observational 
studies. At baseline demographics, diagnoses 
and information about prior treatments were 
collected and IOP readings and tolerability 
measures were recorded. IOP measurements 
were made for each eye at baseline (on prior 
treatment or without treatment in treatment-
naïve patients), and at final visit between 6 
to 12 weeks after switching to or initiation 
of medical therapy with preservative-free 
tafluprost 0.0015% using Goldman applanation 
tonometry. Tolerability was determined using a 
five-point scale (very good, good, satisfactory, 
less satisfactory, not acceptable). For the 
evaluation of local tolerability the investigator 
asked the patients to rate the local comfort using 
this five-point scale. Patients’ and physicians’ 
satisfaction with preservative-free tafluprost 
were recorded at the final visit using a four-point 
scale (very satisfied, satisfied, less satisfied, not 
satisfied at all). For the evaluation of the overall 
satisfaction the investigator asked the patients 
to rate their degree of satisfaction on the four-
point scale. 
In total, datasets from 3350 patients were 
collected during the study period. Paired 
t-tests were conducted to compare IOP values 
at baseline with IOP values after treatment 
with tafluprost 0.0015%. Bowker’s test of 
symmetry was used for statistical comparison 
of local tolerability at final visit versus baseline. 
All adverse events were recorded by the 
physician by asking the patient whether any 
unexpected events occurred after changing or 
initiation of medication. 
RESULTS
Patient and Baseline Characteristics
In total, 1227 patients were excluded from the 
evaluation. These included patients for whom 
the time-period between the two visits was <4 or 
>12 weeks (n=808), patients with retrospectively 
collected data (n=349), patients with datasets 
with incomplete IOP readings (n=41), patients 
already treated at baseline with preservative-free 
tafluprost (n=17), and patients with different 
medical treatment for the right and left eye and 
with data that were not plausible (n=12). After 
the exclusion of these patients, 2123 patients 
of the initial dataset collected were eligible for 
the final evaluation. As shown in Table 1, the 
majority of the patients was female and suffered 
from primary open angle glaucoma. Poor local 
tolerance was the most common reported reason 
578 Adv Ther (2011) 28(7):575-585.
Patient characteristics
Mean age (range)
   SD 





   Male 
   Female 










   Ocular hypertension 
   Primary open angle glaucoma 
   Normal tension glaucoma 
   Pseudo exfoliation glaucoma 
   Other glaucomas 
   Pigment dispersion glaucoma 
   Narrow angle glaucoma 
   Multiple glaucomas 



















for changing medication to preservative-free 
tafluprost (41.1%), followed by a lack of efficacy 
of the prior treatments (25.6%; Figure 1). 
n.d.=no data.
Table 1. Characteristics of the patient population  





















































































0.4%* 0.4%* 0.2%* 0.1%* 0.1%* 0.1%* 0.0%* 0.9%*
16.4%*
Figure 1. Reasons for changing therapy to preservative-free tafluprost 0.0015%, adding preservative-free tafluprost 0.0015% 
to an existing medical treatment regimen, or initiating therapy with preservative-free tafluprost 0.0015%. *Multiple entries.
In patients reporting a local intolerance at 
baseline, irritation was the most frequent 
symptom (36.6%) followed by hyperemia 
(27.3%), allergy (17.3%), and itching (16.8%; 
Figure 2).
Prior Glaucoma Medication
Prior to change of medication, patients used a 
variety of other glaucoma products (n=1673; 
78.8%) or were naïve to treatment (n=450; 
21.2%). The majority of patients were treated 
with a monotherapy (n=1133; 53.4%), most 
frequently with a prostaglandin analog (PGA; 
n=453; 21.3%) or a beta blocker (n=372; 17.5%). 
Five-hundred and forty patients (25.4%) were 
treated with fixed- or nonfixed combinations 
(Table 2).
Effect on IOP
In the overall patient population, IOP was 
significantly reduced from 19.5±4.4 mmHg 
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≤14 mmHg (Figure 4). Overall the IOP was lower 
at the final visit compared with the baseline 
visit in 3224 eyes (76.6%), equal in 467 eyes 
(11.1%), and higher in 519 eyes (12.3%; Figure 
5). The mean IOP was reduced in treatment-
naïve patients and in all patient subgroups 
with prior monotherapy that were switched to 
monotherapy with preservative-free tafluprost. 
At the final visit, 6-12 weeks after initiating 
medical therapy with preservative-free tafluprost 
or after changing medication to a monotherapy 
with preservative-free tafluprost, the mean IOP 
values were significantly lower than at baseline 
(P<0.001). Preservative-free tafluprost also 
lowered IOP significantly in all monotherapy-
subgroups: treatment-naïve patients (n=440): 
22.6±3.9 mmHg (baseline) to 16.7±2.7 mmHg 
(week 6-12); beta blockers (n=307): 20.3±3.5 
mmHg (baseline) to 16.7±2.6 mmHg (week 
6-12); carbonic anhydrase inhibitors (CAIs) 
(n=158): 19.0±3.6 mmHg (baseline) to 16.0±2.6 
mmHg (week 6-12); PGAs (n=447): 16.8±2.9 
mmHg (baseline) to 15.8±2.6 mmHg (week 
6-12). In Figure 6, the mean IOP ± SD is shown 
for treatment-naïve patients and the subgroups 
of patients who had been previously treated 
with beta-blocker monotherapy, alpha-2-
adrenergic receptor agonist monotherapy, CAI 
monotherapy, and PGA monotherapy and were 
switched to a monotherapy with preservative-
free tafluprost. 
In treatment-naïve patients, the mean 
IOP at the final visit was lowered by –5.9 
mmHg, in patients with prior beta-blocker 
monotherapy by –3.6 mmHg, in patients 
with prior alpha-2-adrenergic receptor 
monotherapy by –3.1 mmHg, in patients with 
prior CAI monotherapy by –3.0 mmHg, and 
in patients with a PGA monotherapy by –1.0 
mmHg. Preservative-free tafluprost was also 
used adjunctively to an existing monotherapy 





















Figure 2. Local intolerances of prior medication at 
baseline stratified by type. Percentages refer to all patients 
(n=2123). Multiple entries were possible. *Multiple entries.
Prior treatment (type) n %
Treatment-naïve patients 450 21.2
Monotherapy 1133 53.4
   Beta blockers 372 17.5
   Prostaglandins 453 21.3
    Alpha-2-adrenergic 
receptor agonists
111 5.2
   CAIs 187 8.8
Miotics 10 0.5
Combination therapy 540 25.4
   Fixed combinations 307 14.5
    Nonfixed combinations  (2 
ingredients)
104 4.9





Table 2. Prior therapy used before initiating, switching, or 
adding preservative-free tafluprost 0.0015%.
at baseline to 16.4±2.9 mmHg (P<0.001) 
with preservative-free tafluprost therapy at 
the final visit (Figure 3). Among all patients, 
(n=2123) 79.4% of eyes achieved an IOP level of 
≤18 mmHg, 50.9% of ≤16 mmHg, and 24.4% of 
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when preservative-free tafluprost was added 
to an existing monotherapy, the IOP was 
further reduced at the final visit. When given 
adjunctively to a prior monotherapy treatment 
regimen preservative-free tafluprost provided 
an additional IOP lowering effect: in patients 
with prior beta-blocker treatment the mean 
IOP decreased by –4.5 mmHg, in patients with 
prior CAI monotherapy by –3.8 mmHg, and in 
patients with prior alpha-2-adrenergic receptor 
monotherapy by –3.9 mmHg (Figure 7).
Local Tolerability and Patient Satisfaction
Tolerability improved in the majority of patients 
after medication was changed to preservative-free 
tafluprost. At baseline, tolerability of the prior 
treatment was rated as “very good” and “good” 
by only 28.3% of the patients; 38.4% of patients 
rated the tolerability as “less satisfactory”, and 
18% as “not acceptable.” Tolerability improved 
after the change of medication to preservative-
free tafluprost; a total of 85.7% of patients rated 
the tolerability as “very good” and “good” 
(Figure 8). Specifically in patients treated with 
prior PGA monotherapy improvement of local 
tolerability was evident: at baseline only 1.3% 
and 8.3% of patients rated the local tolerability 
of their prior PGA treatment regimen with “very 
good” or “good” respectively. After the change 
of medication in these patient subgroups to 
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Figure 3. Mean intraocular pressure (IOP) ± SD for all 
patients. *P<0.001 vs. corresponding baseline, paired t-test 
(last observation carry forward [LOCF] analysis).
Figure 5. Comparison of intraocular pressure (IOP) of 
individual patients/eyes at baseline vs. final visit.
Figure 4. Intraocular pressure (IOP) levels at final visit 
6-12 weeks after changing or initiation of medical therapy 
with tafluprost 0.0015%.
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improved: local tolerability was rated as “very 
good” and “good” by 39.6% and 46.3% of 
patients, respectively (Figure 9). As shown in 
Figure 10, at the final visit most patients (92.9%) 
and physicians (92.6%) were very satisfied or 
satisfied with using preservative-free tafluprost. 
Adverse Events and Discontinuations 
Only a few adverse events occurred during the 
treatment period. Therapy with preservative-
free tafluprost was continued after the final 





























































Baseline (prior treatment) Final visit
Very good Good Satisfactory


















Baseline (prior PGA monotherapy) Final visit
Very good Good Satisfactory



































Figure 6. Mean intraocular pressure (IOP) (± SD) for the 
different monotherapy subgroups. *P<0.001.
Figure 8. Tolerability rating at baseline (prior medication) 
and at final visit (preservative-free tafluprost). n=1741 
patients with ratings at baseline and at final visit.
Figure 9. Tolerability rating at baseline (prior PGA 
monotherapy) and at final visit (preservative-free 
tafluprost). n=447 patients.
Figure 7. Mean intraocular pressure (IOP) for subgroups 
of patients when preservative-free tafluprost was given 
adjunctively to an existing monotherapy treatment 
regimen.
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patients (0.8%) discontinued medical treatment 
with preservative-free tafluprost due to local 
intolerance, six patients (0.3%) due to efficacy 
issues, four patients complained about systemic 
side effects (0.2%), and two patients preferred 
to use a multidose treatment regimen (0.2%). 
Details are given in Table 3.
DISCUSSION
In  the  pat ient  populat ion of  th i s 
noninterventional, open-label, multicenter 
observational study, medication was changed 
for two main reasons: first, many patients were 
switched to preservative-free tafluprost because 
of tolerability issues with their prior medication. 
Local intolerance accounted for 41.1% of 
changes of treatment in all patients. Second, 
medical treatment was changed because of lack 
of efficacy of prior medication in 25.6% of all 
patients. Irritation (36.6%), hyperemia (27.3%), 
allergy (17.3%), and/or stinging (16.8%) were 
the most common symptoms at baseline 
before changing medical therapy. The results 
demonstrate that preservative-free tafluprost can 
achieve good IOP control in this difficult patient 
population. The mean IOP in this patient cohort 
at baseline was relatively low, 19.5±4.4 mmHg. 
This may be explained by the relatively high 
number of patients who were treated either with 
a PGA monotherapy (n=453; 21.3%) or a fixed 
or nonfixed combination (n=540; 25.4%) at 
Table 3. Discontinuations until and after the final visit.







Local and systemic intolerance 1 0.0
Local intolerance 14 0.7
Local intolerance and allergy 1 0.0
Not medication related 1 0.0
Patient preference 6 0.3
Surgery 4 0.2
Systemic intolerance 4 0.2
Unknown 2 0.1
Total terminations 46 2.2
Therapy continued 2077 97.8













Very satised Satised Less satised
Not satised No data
Very satised Satised Less satised
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baseline before changing medication. Regardless 
of the low mean baseline IOP, lower IOP values 
were achieved 6-12 weeks after changing 
medication in more than three-quarters of all 
eyes (n=3224 eyes, 76.6%). The IOP remained 
at the same level in 467 eyes (11.1%), and was 
higher in 519 eyes (12.3%) of all eyes. 
There are several explanations for the higher 
IOP at the final visit compared with the baseline 
visit: first, even a relatively small increase of 
1 mmHg compared with treated low baseline 
IOPs is counted as an increase. Second, patients 
with prior fixed combinations that were 
switched to a monotherapy with preservative-
free tafluprost in order to reduce possible side 
effects were included in this analysis. Finally, 
patients whose IOPs were well-controlled 
by their prior PGA monotherapy who were 
switched to preservative-free tafluprost due to 
tolerability issues may also explain this finding. 
In 79.4% of all eyes IOP values of ≤18 mmHg 
were achieved at the final visit, IOP values of 
≤16 mmHg were achieved in more than half of 
the eyes (50.9%), and IOP values of ≤14 mmHg 
were achieved in slightly less than a quarter 
of all eyes (24.4%). The change of medical 
treatment in patients treated with a prior 
monotherapy to preservative-free tafluprost 
provided a significant additional reduction 
in the mean IOP. Furthermore, when given 
adjunctively to an existing monotherapy with 
beta blockers, CAIs, or alpha-2-adrenergic 
receptor agonists, preservative-free tafluprost 
provided an additional decrease in the mean 
IOP. At the final visit, local tolerability increased 
compared with baseline. This was especially 
evident in the patient subgroup using preserved 
prostaglandins at baseline. Consequently, 
a high number of patients and physicians 
rated their satisfaction with preservative-free 
tafluprost at the final visit as “very satisfactory” 
or “satisfactory”. 
Clinical studies show that a high proportion 
of glaucoma patients that were treated with 
preserved glaucoma medications developed 
symptoms such as burning and stinging, 
foreign-body sensation, dry eye, and other 
symptoms consistent with ocular surface 
irritation.17-21  As shown in previous studies, 
the present results confirm that patients with 
irritation of the ocular surface, subjective 
symptoms, and clinical signs,  such as 
hyperemia, may benefit from a change of 
medication to preservative-free tafluprost.22,23
Many experimental and clinical studies have 
clearly demonstrated that the long-term use 
of topical drugs containing preservatives may 
induce changes in the ocular surface, tear film 
instability, epithelial apoptosis, conjunctival 
inflammation, and the loss of goblet cells.18,24,25
After switching to preservative-free tafluprost, 
local tolerability improved in most patients, 
and the overall patient satisfaction with their 
glaucoma treatment increased. The present 
study did not reveal any causal relationship 
between the preservative-free nature of 
tafluprost and the improvement in tolerability. 
Beside the preservative-free nature of the 
drug, the low concentration of tafluprost itself 
may contribute to the improvement of local 
tolerability and patient satisfaction seen in this 
observational study. 
The present study had both strengths 
and limitations. The observational design 
may better reflect the actual clinical practice 
compared with controlled clinical trials. Due 
to its observational nature, the study did not 
reveal any causal relationships. The observed 
reduction in IOP after switching might be 
ascribed to the improvement of subjective 
symptoms and clinical signs, and thus, a 
better compliance. However, regression to 
the mean cannot be ruled out in the present 
study design as a control group was not used. 
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It can be assumed that this patient population 
is representative of patients who are likely to 
be prescribed a preservative-free glaucoma 
medication. However, further studies with 
higher numbers of patients in the different 
subgroups are necessary to determine what 
aspects of preservative-free therapy with 
tafluprost account for the observed treatment 
effects.
CONCLUSION
Preservative-free tafluprost 0.0015% was 
effective, well tolerated, and associated with 
fewer adverse events compared with baseline 
medications. A change of medical therapy to 
preservative-free tafluprost may be beneficial, 
especially for patients with subjective ocular 
symptoms and patients with sensitive or 
dry eyes but also for patients who are not 
responding adequately to other monotherapy 
treatment regimens. A further reduction in the 
IOP was achieved in patients who were switched 
from other monotherapies, including beta-
blockers, CAIs, and PGAs to monotherapy with 
preservative-free tafluprost.
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